Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA07 in CD7+ Relapsed/Refractory Hematolymphoid Malignancies
NCT07338604Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA07 in hematolymphoid malignancies, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse Events at 24 months. Started Dec 2025; status: recruiting.
02
Drugs
UTAA07
03
Conditions
hematolymphoid malignancies
Beyond the preview
Go deeper on NCT07338604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338604.